surmount-1 tirzepatide trial weight loss non-diabetic (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants SURMOUNT-1 Trial - Cardionerds Twitter
Description
If Phase 3 data hold up, it becomes less about modality disruption and more about competitive differentiation inside the SM class
Prader-Willi syndrome presents unique metabolic challenges that standard weight loss approaches often fail to address
Get safe, high-quality compounded medications in Washington
snacking market...
While the world gets thinner, your portfolio shouldnt
Millions of Medicare beneficiaries could save tens of thousands a year as the Feds make a multibillion dollar bet.
